Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database
Authors' conclusion
Our findings emphasize the need for cautious prescribing and further research to ensure the safe use of these medications.
Study context
- Population
- Individuals with reports of adverse events associated with GLP-1 RAs approved for obesity (liraglutide, semaglutide, tirzepatide) in VigiBase
- Participants
- 24,725 / 21,454 / 11,538
- Exposure
- Liraglutide vs semaglutide vs tirzepatide
- Liraglutiden = 24,725
- Semaglutiden = 21,454
- Tirzepatiden = 11,538
- Outcome
- Adverse drug reaction patterns (aROR and IC)
Methodological detailscase-control design, VigiBase, multivariable logistic regression
- Case-control design
- VigiBase
- Multivariable logistic regression
Main finding
As reported in the abstract
Semaglutide: suicidal ideation and behaviour, aROR
2.52 (2.18-2.93); IC 1.53 [IC025, 1.28] (95% CI)
Semaglutide: hair loss, aROR
1.42 (1.30-1.55); IC 0.78 [IC025, 0.63] (95% CI)
Semaglutide: vision loss, aROR
1.80 (1.66-1.97); IC 1.27 [IC025, 1.13] (95% CI)
Observational data: associations, not effects.
Original publication
Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes Obes Metab. Published 2 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →